Novavax’s stock surges after supply deal with South Korea’s SK Group for COVID-19 vaccine candidate

Shares of Novavax Inc.
rallied 2.8% in premarket trading Thursday, after the biotechnology company said it has entered into a development and supply agreement with South Korea-based SK Group subsidiary SK Bioscience for the antigen component of Novavax’s COVID-19 vaccine candidate, NVX-CoV2373. The companies have also signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to make NVX-CoV2373 available in South Korea, as well as for the global ma…

Click here to view the original article.